• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: Community series in immunotherapy with checkpoint inhibitors for non-small cell lung cancer, colon cancer, and esophageal cancer, volume II.

作者信息

Li Yueyi, Wang Yusha, Gao Jinsheng, Tan Keqin, Frey Benjamin, Gaipl Udo S, Shi Hubing, Ma Xuelei

机构信息

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

People's Hospital of Yilong County, Nanchong, Sichuan, China.

出版信息

Front Immunol. 2023 Jul 3;14:1222675. doi: 10.3389/fimmu.2023.1222675. eCollection 2023.

DOI:10.3389/fimmu.2023.1222675
PMID:37465680
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10352080/
Abstract
摘要

相似文献

1
Editorial: Community series in immunotherapy with checkpoint inhibitors for non-small cell lung cancer, colon cancer, and esophageal cancer, volume II.社论：非小细胞肺癌、结肠癌和食管癌免疫检查点抑制剂治疗社区系列，第二卷。
Front Immunol. 2023 Jul 3;14:1222675. doi: 10.3389/fimmu.2023.1222675. eCollection 2023.
2
Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.免疫检查点抑制剂在非小细胞肺癌免疫治疗中的最新进展和挑战。
Int Immunopharmacol. 2020 Aug;85:106613. doi: 10.1016/j.intimp.2020.106613. Epub 2020 May 22.
3
[Cost Effectiveness and Health Economics of Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer].免疫检查点抑制剂用于非小细胞肺癌的成本效益与卫生经济学
Gan To Kagaku Ryoho. 2018 May;45(5):781-784.
4
Immunotherapy in advanced non-small-cell lung cancer with mutations.携带 突变的晚期非小细胞肺癌的免疫治疗。
Immunotherapy. 2020 Nov;12(16):1195-1207. doi: 10.2217/imt-2020-0148. Epub 2020 Sep 27.
5
[Application Progress of Immune Checkpoint Inhibitors 
in Oncogene-driven Advanced Non-small Cell Lung Cancer].[免疫检查点抑制剂在癌基因驱动的晚期非小细胞肺癌中的应用进展]
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):188-195. doi: 10.3779/j.issn.1009-3419.2021.101.04.
6
The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice.免疫检查点抑制剂联合化疗治疗晚期非小细胞肺癌：合理选择。
Immunotherapy. 2022 Feb;14(2):155-167. doi: 10.2217/imt-2021-0014. Epub 2021 Dec 6.
7
The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.ERBB4 突变在免疫检查点抑制剂治疗晚期非小细胞肺癌中的预后作用。
Mol Med. 2021 Oct 7;27(1):126. doi: 10.1186/s10020-021-00387-z.
8
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
9
Chemo and Immuno-Therapeutic Options for Nonsmall Cell Lung Cancer Lung Cancer.非小细胞肺癌的化疗和免疫治疗选择 肺癌。
Surg Clin North Am. 2022 Jun;102(3):493-498. doi: 10.1016/j.suc.2022.02.005.
10
[Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].[晚期非小细胞肺癌且PD-L1高表达患者对免疫检查点抑制剂单药治疗或联合化疗反应的评估]
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):161-166. doi: 10.3779/j.issn.1009-3419.2021.103.02.

本文引用的文献

1
Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.免疫检查点抑制剂治疗携带表皮生长因子受体突变的非小细胞肺癌患者的临床结局。
BMC Pulm Med. 2023 May 5;23(1):158. doi: 10.1186/s12890-023-02466-9.